Physician profile
William M Fallin
NPI 1649477407
$2,098.62
in general payments reported to CMS, 2019-2025
19 companies · $52.70 in 2025
The $52.70 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $482 · 2023: $544 · 2024: $260 · 2025: $52.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.67 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $359.04 | 2021-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $200.89 | 2021-2023 | Verquvo |
| Novo Nordisk INC | $199.99 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $116.26 | 2021-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $97.87 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $87.12 | 2024-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $82.06 | 2021 | |
| Amgen INC. | $56.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.90 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.92 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.94 | 2021-2023 | Synjardy, Jardiance |
| Esperion Therapeutics, INC. | $41.00 | 2021-2024 | Nexletol |
| Pfizer INC. | $30.98 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.28 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.67 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fallin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.